Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity.
Treatment of severe retinopathy of prematurity (ROP) has evolved over the last decade. This article reviews recent clinical trials and experimental evidence that supports clinical outcomes and observations, including the efficacy of anti-vascular endothelial growth factor (VEGF) agents in reducing the vascular activity of severe ROP, and the mechanisms behind recurrent stage 3 ROP and plus disease in some infants treated with anti-VEGF agents. Also discussed will be current imaging modalities that link experimental models of ROP with longitudinal human studies and which provide exciting future opportunities to enhance the understanding of pathophysiology of ROP and improve treatments. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:228-234.].
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Tomography, Optical Coherence
- Retinopathy of Prematurity
- Receptors, Vascular Endothelial Growth Factor
- Laser Therapy
- Intravitreal Injections
- Humans
- Fundus Oculi
- Fluorescein Angiography
- Clinical Trials as Topic
- Bevacizumab
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Tomography, Optical Coherence
- Retinopathy of Prematurity
- Receptors, Vascular Endothelial Growth Factor
- Laser Therapy
- Intravitreal Injections
- Humans
- Fundus Oculi
- Fluorescein Angiography
- Clinical Trials as Topic
- Bevacizumab